ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI) Files An 8-K Results of Operations and Financial Condition
Item2.02
|
Results of Operations and Financial Condition. |
On May15, 2017, OncoGenex Pharmaceuticals, Inc. (the Company)
issued a press release announcing its financial results for the
first quarter of 2017. A copy of the press release is furnished
as Exhibit99.1 to this Current Report on Form 8-K.
| Item9.01. | Financial Statements and Exhibits. |
(d) Exhibits
|
Exhibit No. |
Description |
|
| 99.1 |
Press release of OncoGenex Pharmaceuticals, Inc. dated May15, 2017 |
The information in Item 2.02 of this Form 8-K and Exhibit 99.1
attached hereto is furnished and shall not be deemed filed for
purposes of Section18 of the Securities Exchange Act of 1934, as
amended (the Exchange Act), nor shall it be deemed incorporated
by reference in any filing under the Securities Act of 1933, as
amended, or the Exchange Act, except as shall be expressly set
forth by specific reference in such filing.
About ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI)
OncoGenex Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development and commercialization of therapies that address treatment resistance in cancer patients. The Company’s segment is dedicated to the development and commercialization of cancer therapies, with operations located in Canada and the United States. The Company’s product candidates include Custirsen, Apatorsen and OGX-225. The Company is focused on targeting these particular proteins to disable the tumor cell’s adaptive defenses, thereby rendering the tumor cells susceptible to attack with a range of cancer therapies. Of these product candidates, Custirsen and Apatorsen are clinical-stage assets. Custirsen is being evaluated in two Phase III trials. Apatorsen is a product candidate designed to inhibit production of heat shock protein 27 (Hsp27). OGX-225 is a product candidate designed to inhibit the production of Insulin Growth Factor Binding Proteins-2 and -5 (IGFBP-2, IGFBP-5). ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI) Recent Trading Information
ONCOGENEX PHARMACEUTICALS, INC. (NASDAQ:OGXI) closed its last trading session 00.000 at 0.360 with 105,625 shares trading hands.
